ASRA guidelines for patients on anticoagulants

Reading File

Finding Sources

Reading File

I now have comprehensive content from multiple authoritative sources. Let me compile the full ASRA guidelines summary.

ASRA Guidelines: Regional Anesthesia in Patients on Anticoagulants

(Based on ASRA 4th Edition Evidence-Based Guidelines, Horlocker et al. 2018, as summarized in Miller's Anesthesia 10e, Barash Clinical Anesthesia 9e, and Morgan & Mikhail's Clinical Anesthesiology 7e)

Core Principles

The timing of neuraxial needle/catheter insertion and removal should reflect the pharmacokinetic properties of the specific anticoagulant
The risk of spinal hematoma must be weighed against the thromboembolic risk of stopping anticoagulation
Epidural hematoma is rare (~1 in 150,000 epidurals) but devastating — most guidelines are based on expert opinion and case series, not RCTs
Frequent neurologic monitoring is recommended throughout
Concurrent use of multiple agents affecting coagulation (e.g., warfarin + NSAIDs + LMWH) compounds risk

I. Vitamin K Antagonists (Warfarin)

Situation	Recommendation
Pre-block	Stop ≥5 days prior; confirm INR normalization before needle insertion
Catheter removal	INR <1.5: safe to remove
	INR 1.5–3.0: remove with caution
	INR >3.0: hold or reduce warfarin dose; do not remove
Concurrent agents	Avoid ASA, NSAIDs, thienopyridines, UFH, LMWH alongside warfarin neuraxially
Post-removal	Continue neuro monitoring ≥24 h after catheter removal

II. Direct Oral Anticoagulants (DOACs)

Factor Xa Inhibitors

Drug	Pre-block hold	Catheter removal (planned)	If dose given with catheter in situ
Rivaroxaban	72 h	≥6 h before first post-op dose	Wait 22–26 h before removal (or check anti-Xa assay)
Apixaban	72 h (similar to rivaroxaban)	≥6 h before first post-op dose	Wait 26–30 h before removal
Edoxaban	72 h	≥6 h before first post-op dose	Wait 20–28 h or check anti-Xa assay
Betrixaban	3 days (72 h); avoid if CrCl <30 mL/min	≥5 h before resumption	Wait 72 h before removal

If neuraxial is considered <72 h after stopping a factor Xa inhibitor, check anti-factor Xa activity (note: no validated "safe" threshold established).

Direct Thrombin Inhibitor

Drug	Pre-block hold	Catheter removal	If inadvertent dose given
Dabigatran (CrCl >80 mL/min)	72 h	≥6 h before resuming dabigatran	Wait 34–36 h before removal
Dabigatran (CrCl 50–79 mL/min)	96 h	Same	Same
Dabigatran (CrCl 30–49 mL/min)	120 h	Same	Same
Dabigatran (CrCl <30 mL/min)	Neuraxial NOT recommended	—	—

If neuraxial considered <72 h after dabigatran: check direct thrombin time or ecarin clotting time (no validated safe threshold). Thrombin clotting time can also detect dabigatran effect.

III. Heparins

Unfractionated Heparin (UFH)

Context	Recommendation
Subcutaneous (prophylactic)	Perform block 1 h before or 4 h after last dose
IV therapeutic heparin	Discontinue 4–6 h prior; check aPTT/ACT to confirm normal
Intraoperative heparinization	Wait ≥1 h after neuraxial placement before heparin; delay surgery if traumatic needle
Catheter removal	Remove 2–4 h after last heparin dose; reheparinize 1 h after removal

Low Molecular Weight Heparin (LMWH)

Context	Recommendation
Prophylactic dosing	Needle/catheter: wait 12 h after last dose
Therapeutic dosing	Needle/catheter: wait 24 h after last dose
Post-block dosing	Wait 2 h after needle/catheter placement
Catheter removal	Must be ≥12 h since last prophylactic dose; next dose ≥4 h after removal
Monitoring	Anti-Xa levels not reliably predictive; avoid concurrent antiplatelet agents

Fondaparinux (Factor Xa Inhibitor — Parenteral)

Hold 36–42 h prior (2–3 half-lives); consider anti-Xa assay if uncertain
Avoid indwelling catheters; if used, remove before resuming fondaparinux
Long half-life (~17 h) makes this higher risk

IV. Antiplatelet Agents

Drug	Hold before neuraxial block
ASA / NSAIDs	No contraindication (alone, with normal coagulation)
Cangrelor	≥3 h; wait 8 h after block/catheter removal before restarting
Cilostazol	≥48 h; wait 6 h after block/catheter removal
Clopidogrel	5–7 days
Prasugrel	7–10 days
Ticagrelor	5–7 days
Ticlopidine	10 days
Abciximab (GP IIb/IIIa)	24–48 h
Eptifibatide / Tirofiban	4–8 h

ASA/NSAIDs alone do not increase spinal hematoma risk. The concern arises when combined with other anticoagulants.

V. Thrombolytics / Fibrinolytics

Neuraxial block is generally contraindicated within 10 days of thrombolytic therapy
If a patient on thrombolytics has a neuraxial catheter in situ, this is a medical emergency — monitor neurologically every 2 hours and remove catheter only when fibrinogen levels normalize
Check fibrinogen level, PT, aPTT before any removal

VI. General Monitoring & Management Principles

Neurologic monitoring should be performed frequently (every 2 h for epidural catheters in anticoagulated patients)
Any new neurologic deficit (e.g., back pain, leg weakness, bowel/bladder dysfunction) should prompt urgent MRI and neurosurgical consultation
Traumatic needle placement increases risk — consider delaying surgery to allow clinical assessment
Anticoagulant discontinuation should always be coordinated with the prescribing physician (cardiologist, hematologist) to balance thrombotic vs. bleeding risk
Bridging therapy with heparin may be appropriate during DOAC/warfarin interruption in high thrombotic-risk patients

VII. ASRA Preferred Agent Recommendations (Evidence Level A)

For patients with stroke/TIA, atrial fibrillation, VTE, or ATE who need anticoagulation:

Prefer DOAC over warfarin
Prefer DOAC over LMWH
Prefer DOAC over UFH (Based on superior efficacy and safety profiles in trials)

Sources:

Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e — Table 51-3 (ASRA Practice Advisory Summary)
Morgan & Mikhail's Clinical Anesthesiology, 7e — Chapter 45: Neuraxial Blockade and Anticoagulants
Miller's Anesthesia, 10e — Chapters 28, 32, 60 (Perioperative Anticoagulant Management)
Primary source: Horlocker TT, et al. Reg Anesth Pain Med. 2018;43:263–309 (ASRA 4th Edition Guidelines)

This is a shared conversation. Sign in to Orris to start your own chat.